Dahham Alsoud

459 total citations
21 papers, 292 citations indexed

About

Dahham Alsoud is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Dahham Alsoud has authored 21 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 12 papers in Epidemiology and 7 papers in Surgery. Recurrent topics in Dahham Alsoud's work include Inflammatory Bowel Disease (21 papers), Microscopic Colitis (12 papers) and Eosinophilic Esophagitis (3 papers). Dahham Alsoud is often cited by papers focused on Inflammatory Bowel Disease (21 papers), Microscopic Colitis (12 papers) and Eosinophilic Esophagitis (3 papers). Dahham Alsoud collaborates with scholars based in Belgium, Netherlands and United States. Dahham Alsoud's co-authors include Séverine Vermeire, Bram Verstockt, Claudio Fiocchi, Marc Ferrante, João Sabino, Annick Moens, Sare Verstockt, Gert De Hertogh, Debby Thomas and Griet Compernolle and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Dahham Alsoud

20 papers receiving 291 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dahham Alsoud Belgium 9 239 137 73 69 48 21 292
Matthew C. Choy Australia 8 231 1.0× 168 1.2× 69 0.9× 77 1.1× 44 0.9× 22 312
Zhihua Ran China 12 144 0.6× 98 0.7× 64 0.9× 69 1.0× 54 1.1× 27 278
Yuichi Morohoshi Japan 8 151 0.6× 184 1.3× 75 1.0× 84 1.2× 50 1.0× 21 392
Julie Galsgaard Denmark 5 140 0.6× 85 0.6× 124 1.7× 51 0.7× 75 1.6× 6 290
AnnKatrin Petersen United States 5 331 1.4× 200 1.5× 105 1.4× 90 1.3× 109 2.3× 12 483
Miguel Sans Spain 3 153 0.6× 114 0.8× 74 1.0× 62 0.9× 40 0.8× 3 258
Yulan Ye China 7 109 0.5× 92 0.7× 66 0.9× 48 0.7× 132 2.8× 13 320
F Baert Belgium 7 179 0.7× 108 0.8× 56 0.8× 98 1.4× 77 1.6× 16 288
Brian Feagan United States 8 314 1.3× 248 1.8× 105 1.4× 76 1.1× 30 0.6× 34 404
Sarah O’Donnell Ireland 10 103 0.4× 97 0.7× 50 0.7× 114 1.7× 27 0.6× 28 257

Countries citing papers authored by Dahham Alsoud

Since Specialization
Citations

This map shows the geographic impact of Dahham Alsoud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dahham Alsoud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dahham Alsoud more than expected).

Fields of papers citing papers by Dahham Alsoud

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dahham Alsoud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dahham Alsoud. The network helps show where Dahham Alsoud may publish in the future.

Co-authorship network of co-authors of Dahham Alsoud

This figure shows the co-authorship network connecting the top 25 collaborators of Dahham Alsoud. A scholar is included among the top collaborators of Dahham Alsoud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dahham Alsoud. Dahham Alsoud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alsoud, Dahham, Dirk Jan A. R. Moes, Zhigang Wang, et al.. (2024). Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring. 46(3). 291–308. 8 indexed citations
2.
Alsoud, Dahham, João Sabino, Denis Franchimont, et al.. (2024). Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study. Inflammatory Bowel Diseases. 30(12). 2289–2296. 17 indexed citations
3.
Alsoud, Dahham, et al.. (2024). Calibration, Clinical Utility, and Specificity of Clinical Decision Support Tools in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. 23(7). 1216–1227.e14. 1 indexed citations
4.
Alsoud, Dahham, et al.. (2023). Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease. Therapeutic Advances in Gastroenterology. 16. 1108372086–1108372086. 2 indexed citations
5.
Alsoud, Dahham, et al.. (2023). Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis. The American Journal of Gastroenterology. 119(3). 477–485. 3 indexed citations
6.
Alsoud, Dahham, Séverine Vermeire, & Bram Verstockt. (2022). Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises. SHILAP Revista de lepidopterología. 3. 100089–100089. 12 indexed citations
7.
Alsoud, Dahham, João Sabino, Marc Ferrante, Séverine Vermeire, & Bram Verstockt. (2022). P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s disease. Journal of Crohn s and Colitis. 16(Supplement_1). i427–i428. 1 indexed citations
8.
Moens, Annick, Dahham Alsoud, Bram Verstockt, et al.. (2022). Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center. European Journal of Gastroenterology & Hepatology. 34(10). 1015–1020. 13 indexed citations
9.
Verstockt, Bram, Valery Volk, Dahham Alsoud, et al.. (2022). Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Alimentary Pharmacology & Therapeutics. 56(2). 282–291. 9 indexed citations
10.
Verstockt, Bram, Dahham Alsoud, Jeffrey A. Smith, et al.. (2022). P401 Tofacitinib tissue exposure correlates with endoscopic outcome. Journal of Crohn s and Colitis. 16(Supplement_1). i394–i395. 5 indexed citations
11.
Alsoud, Dahham, Gert De Hertogh, Griet Compernolle, et al.. (2022). Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis. Journal of Crohn s and Colitis. 16(10). 1562–1570. 19 indexed citations
12.
Sudhakar, Padhmanand, Dahham Alsoud, Judith Wellens, et al.. (2022). Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All. Journal of Crohn s and Colitis. 16(8). 1306–1320. 15 indexed citations
13.
Alsoud, Dahham, Denis Franchimont, F D’Heygere, et al.. (2022). P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study. Journal of Crohn s and Colitis. 16(Supplement_1). i516–i517. 1 indexed citations
14.
Alsoud, Dahham, Griet Compernolle, João Sabino, et al.. (2022). P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis. Journal of Crohn s and Colitis. 16(Supplement_1). i424–i424. 1 indexed citations
15.
Verstockt, Bram, Dahham Alsoud, Triana Lobatón, et al.. (2021). The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. British Journal of Clinical Pharmacology. 87(10). 3776–3789. 8 indexed citations
16.
Moens, Annick, Bram Verstockt, Dahham Alsoud, et al.. (2021). Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. Inflammatory Bowel Diseases. 28(8). 1135–1142. 16 indexed citations
17.
Alsoud, Dahham, Bram Verstockt, Claudio Fiocchi, & Séverine Vermeire. (2021). Breaking the therapeutic ceiling in drug development in ulcerative colitis. ˜The œLancet. Gastroenterology & hepatology. 6(7). 589–595. 132 indexed citations
18.
Alsoud, Dahham, Sare Verstockt, João Sabino, et al.. (2021). P062 Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease. Journal of Crohn s and Colitis. 15(Supplement_1). S168–S168. 4 indexed citations
19.
Verstockt, Bram, Dahham Alsoud, An Outtier, et al.. (2021). Su462 ONE YEAR ENDOSCOPIC AND HISTOLOGIC OUTCOMES TO TOFACITINIB THERAPY IN REFRACTORY ULCERATIVE COLITIS. Gastroenterology. 160(6). S–702. 1 indexed citations
20.
Alsoud, Dahham, Séverine Vermeire, & Bram Verstockt. (2020). Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?. Current Opinion in Pharmacology. 55. 17–30. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew C. Choy Breakdown of academic impact, for papers by Zhihua Ran Breakdown of academic impact, for papers by Yuichi Morohoshi Breakdown of academic impact, for papers by Julie Galsgaard Breakdown of academic impact, for papers by AnnKatrin Petersen Breakdown of academic impact, for papers by Miguel Sans Breakdown of academic impact, for papers by Yulan Ye Breakdown of academic impact, for papers by F Baert Breakdown of academic impact, for papers by Brian Feagan Breakdown of academic impact, for papers by Sarah O’Donnell
Rankless by CCL
2026